Biomerica (NASDAQ:BMRA) released its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.06), Fidelity Earnings reports. Biomerica had a negative net margin of 34.95% and a negative return on equity of 36.23%.
Shares of Biomerica stock opened at $5.84 on Friday. Biomerica has a 12-month low of $2.05 and a 12-month high of $23.39. The stock has a market cap of $68.64 million, a P/E ratio of -25.39 and a beta of -0.83. The business’s 50 day moving average is $7.13 and its 200-day moving average is $7.54.
Separately, Aegis boosted their target price on Biomerica from $10.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, September 4th.
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Further Reading: What is the Difference Between Common Shares and Convertible Shares?
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.